Infraredx, which markets a FDA-cleared optical catheter that identifies lipid core coronary plaques, announced terms for its IPO on Tuesday. The Burlington, MA-based company plans to raise $56 million by offering 4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Infraredx would command a fully diluted market value of $213 million.
Infraredx, which was founded in 1998 and booked $5 million in sales for the 12 months ended September 30, 2014, plans to list on the NASDAQ under the symbol REDX. RBC Capital Markets, Canaccord Genuity and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of January 26, 2015.
Help employers find you! Check out all the jobs and post your resume.
